The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to the securities has been filed with the Securities and
Exchange Commission. This preliminary pricing supplement is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or
sale of securities is not permitted.
Subject to Completion, dated June 18, 2012
|
|
Preliminary Pricing Supplement No. 58
(To Prospectus Supplement dated November 25, 2011
and Prospectus dated December 22, 2010)
|
Filed Pursuant to Rule 424(b)(5)
Registration Nos. 333-167844 and 333-167844-01
June 18, 2012
|
CUSIP/
ISIN
|
Aggregate
Principal
Amount
|
Price to
Public(1)
|
Selling
Agent’s
Commission(2)
|
Net
Proceeds
|
Interest
Type
|
Interest
Rate
|
Interest
Payment
Frequency
|
Day
Count
Fraction
|
Business
Day
Convention
|
Maturity
Date
|
First
Interest
Payment
Date
|
First
Interest
Payment
Amount
|
Survivor’s
Option
|
Ranking
|
|
53944XCK9/
US53944XCK90
|
$
|
Per Note:
|
$1,000
|
$6.50
|
$993.50
|
Fixed |
2.50% per annum
|
Semi-annually | 30/360 | Following, unadjusted, New York and London |
6/28/2016
|
12/28/2012
|
$12.50 (per $1,000 Note)
|
Yes | Senior Unsecured |
Total:
|
$
|
$
|
$
|
Redemption Information: Non-Callable
|
Selling Agent: Barclays Capital Inc.
|
Lloyds TSB Bank plc
fully and unconditionally
guaranteed by
Lloyds Banking Group plc
Retail Notes, Series B
|
Offering Dates:
|
June 18, 2012 through June 25, 2012
|
Notes:
|
Retail Notes, Series B
|
Trade Date:
|
June 25, 2012
|
Issuer:
|
Lloyds TSB Bank plc (“Lloyds Bank”)
|
|
Issue Date:
|
June 28, 2012
|
Guarantor:
|
Lloyds Banking Group plc (“LBG”)
|
|
Minimum Denomination/Increments: $1,000/$1,000
Settlement and Clearance: DTC; Book-Entry
Listing: The Notes will not be listed or displayed on any securities exchange or quotation system.
Survivor’s Option Payment Date: Subject to limitations, each February 15 and August 15 of each calendar year. See “Risk Factors — Any Survivor’s Option may be limited in amount, and any repayments made with respect to the exercise of a Survivor’s Option will not be made immediately” and “Description of the Survivor’s Option” starting on page S-6 and page S-17, respectively, in the accompanying prospectus supplement.
Interest Payment Dates: Interest on the Notes will be paid semi-annually in arrears on the 28th day of each June and December (each an “Interest Payment Date”) beginning on (and including) December 28, 2012 and ending on the Maturity Date or the Survivor’s Option Payment Date, if applicable. For additional information see “Description of the Notes and the Guarantees — Payment of Principal, Interest and Other Amounts Due” starting on page S-10 in the accompanying prospectus supplement.
If an Interest Payment Date, the Maturity Date or the Survivor’s Option Payment Date, if applicable, for any Note is not a business day (as defined in the accompanying prospectus supplement), principal, premium, if any, and interest for that Note will be paid on the next business day, and no additional interest will accrue in respect of such payments made on the next business day.
Any payments due on the Notes, including any repayment of principal, will be subject to the creditworthiness of Lloyds Bank, as the Issuer, and LBG, as the Guarantor of the Issuer’s obligations under the Notes. A leading rating agency has placed certain of the Issuer's ratings, including its long-term ratings, under review for a downgrade (in accordance with its review of the ratings of Western European banks in general), and according to an announcement by that rating agency dated April 13, 2012, the review of the UK banks placed under review may be concluded before the end of June 2012. Such rating action may therefore fall on a date between the date hereof and the date of delivery of the Notes. There can however be no assurance as to the actual timing of the conclusion of such review or any such rating action.
LBG and Lloyds Bank have filed a registration statement with the SEC for the offering to which this pricing supplement relates. Before you invest, you should read this pricing supplement together with the prospectus dated December 22, 2010 (the “prospectus”) in that registration statement and other documents, including the more detailed information contained in the prospectus supplement dated November 25, 2011 (the “prospectus supplement”), that LBG and Lloyds Bank have filed with the SEC for more complete information about LBG and Lloyds Bank and this offering. You may access these documents on the SEC website at.www.sec.gov. LBG’s Central Index Key, or CIK, on the SEC website is 1160106 and Lloyds Bank’s CIK on the SEC website is 1167831. The prospectus supplement and the prospectus may be accessed as follows (or if such address has changed, by reviewing LBG’s and Lloyds Bank’s filings for the relevant date on the SEC website):
· prospectus supplement dated November 25, 2011 and prospectus dated December 22, 2010:
You may revoke your offer to purchase the Notes at any time prior to the time at which your offer is accepted on the Trade Date by notifying the Selling Agent. Lloyds Bank has the right to change the terms of, or reject any offer to purchase the Notes in whole or in part. The Selling Agent also has the right to reject any offer it solicited to purchase the Notes. In the event of any changes to the terms of the Notes, Lloyds Bank or the Selling Agent will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case your offer to purchase the Notes may be rejected.
Investing in the Notes involves significant risks. See “Risk Factors” beginning on page S-3 of the accompanying prospectus supplement.
The Notes are not bank deposits and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency.
None of the Securities and Exchange Commission, any state securities commission and any other regulatory body has approved or disapproved of these Notes or passed upon the adequacy or accuracy of this pricing supplement, the accompanying prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
|